Furthermore, we explored the pharmaceutical effect of a combination therapy with tricin and an anti-PD-1 inhibitor, providing new ideas for research on combination treatment for patients with KRAS-mutant NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.